Exclusive Summary

• - Off-patent globally; the 0.25 mg once-daily regimen is a cross-country standard within GnRH antagonist protocols.
• - Stable, growing demand: ~4–5 million IVF/ICSI cycles annually worldwide, with 60–80% using antagonist protocols and typically 5–7 doses per cycle.
• - Guideline-endorsed with lower OHSS risk vs agonist protocols; strong substitutability and easy adoption by IVF centers.
• - US submitted provides a high-regulation entry credential, enabling multi-region distribution and registration partnerships.
• - Generic pricing typically 20–50% below originator (30–60% in tenders), materially improving uptake in self-pay and tender markets.